

# **CURRICULUM VITAE**

**EMPLOYEE NAME: GARY MEININGER, MD**

**DATE: December 17, 2019**

**SITE:** Boston

**DIVISION:** Vertex Pharmaceuticals

**DEPARTMENT:** Global Medical Development and Affairs (GMDA)

# CURRICULUM VITAE

EMPLOYEE NAME: **GARY MEININGER, MD**

DATE: **December 17, 2019**

<b>EDUCATION:</b>	<b><u>School</u></b>	<b><u>Date</u></b>	<b><u>Degree</u></b>
	State University of New York at Binghamton Binghamton, New York	August 1988 – May 1992	Bachelor of Science, Biological Sciences
	New York University School of Medicine New York, New York	August 1992 – May 1996	Doctor of Medicine
	The New York-Presbyterian Hospital – Cornell University Medical Center New York, New York	June 1996 – June 1999	Categorical Internal Medicine Residency
	The Massachusetts General Hospital, Department of Endocrinology Boston, Massachusetts	June 1999 – June 2002	Endocrinology Clinical and Research Fellow

## LICENSURES / CERTIFICATIONS:

Board Certified in Endocrinology, Diabetes, and Metabolism (2001)

## EMPLOYMENT

2/2019- Present	Senior Vice President, Head of Pipeline Development Global Medical Development and Medical Affairs Vertex Pharmaceuticals Boston, Massachusetts
6/2010- 2/2019	Janssen Research and Development Pharmaceutical division of Johnson & Johnson Raritan, New Jersey

# CURRICULUM VITAE

EMPLOYEE NAME: **GARY MEININGER, MD**

DATE: **December 17, 2019**

- 6/2010-2/2019 Vice President – Franchise Medical Leader – Metabolism, Janssen Research and Development, Cardiovascular-Metabolism Therapeutic Area
- Provide leadership, direction, and guidance on clinical development strategy for all programs in late clinical development, including for canagliflozin (INVOKANA®), canagliflozin/metformin fixed-dose combination (INVOKAMET® IR and XR [US] and VOKANAMET® IR [ex-US])
    - Numerous health authority and related interactions (eg, FDA, CHMP, COFEPRIS), including presenter at FDA Advisory committee for INVOKANA® (January 10, 2013)
    - Molecule Responsible Physician for canagliflozin lifecycle management program, which included 2 cardiovascular outcome studies (CANVAS and CANVAS-R), a renal outcomes study (CREDENCE), T1DM Phase 2 study, Obesity (canagliflozin/phentermine) Phase 2 study, and pediatric program
    - Steering Committee member for CANVAS program and CREDENCE study
  - Provide guidance and strategic input in the development and completion of protocols, SAPs, regulatory documents, manuscripts; Protocol/Statistical Analysis Plan Review Committee co-chair
  - Provide mentoring and support to build, develop, and motivate all staff within the late development group
  - Collaborate with others (including on early development programs, publications, medical affairs, commercial, licensing/business development) to provide direction, strategy, and input on cross-functional/therapeutic area/sector teams, with goal of supporting efficient and timely progression into or within late development
    - Core member of Metabolism Disease Area Leadership Team (cross-functional team responsible for advancing internal and in-licensed compounds from Discovery through Late Development) and of prior/ongoing partnerships with biotech with clinical assets
    - Primary clinical presenter at several face-to-face payer meetings
  - Co-author of accepted European Innovative Medicines Initiative (IMI)-2 pre-competitive, cross-pharma proposal to create a non-alcoholic steatohepatitis (NASH) platform study (Call 15; July 2018)

# CURRICULUM VITAE

EMPLOYEE NAME: **GARY MEININGER, MD**

DATE: **December 17, 2019**

7/2002-  
6/2010

Merck Research Laboratories

Rahway, New Jersey

2005-2010 Director, Merck Research Laboratories, Metabolism

- Product Development Team Leader for two programs which advanced through Phase 2b (glucokinase activator program and separate program [undisclosed molecular target])
- Metabolism Department's primary clinical representative to Metabolism Licensing Committee

2002-2005 Associate Director, Merck Research Laboratories, Metabolism

- Core member of Januvia™ (sitagliptin)/Janumet™ (sitagliptin/metformin) team, including responsibility for conduct of several key studies in worldwide filings

Summers  
1987-1992

Metpath Clinical Laboratories, Inc. (now Quest Diagnostic Laboratories, Inc.)

Teterboro, New Jersey

Licensed laboratory technician, Department of Virology and Genetics

# CURRICULUM VITAE

EMPLOYEE NAME: **GARY MEININGER, MD**

DATE: **December 17, 2019**

## CURRENT PROFESSIONAL AFFILIATIONS

American Diabetes Association (ADA)  
American Society of Nephrology (ASN)  
Kidney Health Initiative (KHI)  
American Society of Hematology (ASH)

## PUBLICATIONS

### Manuscripts

**Meininger G.**, Hadigan C., Laposata M., Brown J., Rabe J., Louca J., Aliabadi, N., and Grinspoon S. (February 2002) "Elevated Concentrations of Free Fatty Acids Are Associated With Increased Insulin Response to Standard Glucose Challenge in Human Immunodeficiency Virus-Infected Subjects With Fat Redistribution". Metabolism. Vol. 51 (2): Pp. 260-266.

**Meininger G.**, Hadigan C., Rietschel P., and Grinspoon S. (August 2002) "Body-composition measurements as predictors of glucose and insulin abnormalities in HIV-positive men". American Journal of Clinical Nutrition. Vol. 76(2): Pp. 460-465.

Hadigan C., Rabe J., **Meininger G.**, Aliabadi N., Breu J., Grinspoon S. (February 2003) "Inhibition of lipolysis improves insulin sensitivity in protease inhibitor-treated HIV-infected men with fat redistribution". American Journal of Clinical Nutrition. Vol. 77 (2): Pp. 490-494.

Koutkia P., **Meininger G.**, Canavan B., Breu J., Grinspoon S. (February 2004) "Metabolic regulation of growth hormone by free fatty acids, somatostatin, and ghrelin in HIV-lipodystrophy". Am J Physiol Endocrinol Metab. Vol. 286 (2): Pp. E296-303.

Driscoll S., **Meininger G.**, Lareau M., Dolan S., Killilea K., Hadigan C., Lloyd-Jones D., Klibanski A., Frontera W., Grinspoon S. (February 20, 2004) "Effects of exercise training and metformin on body composition and cardiovascular indices in HIV-infected patients". AIDS. Vol. 18 (3): 465-473.

Driscoll S., **Meininger G.**, Ljungquist K., Hadigan C., Torriani M., Klibanski A., Frontera W., Grinspoon S. (May 2004) "Differential effects of metformin and exercise on muscle adiposity and metabolic indices in human immunodeficiency virus-infected patients". J Clin Endocrinol Metab. Vol. 89 (5): 2171-2178.

Charbonnel B., Karasik A., Liu J., Wu M., **Meininger G.** (December 2006) "Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone". Diabetes Care. Vol 29 (12): 2638-2643.

# CURRICULUM VITAE

EMPLOYEE NAME: **GARY MEININGER, MD**

DATE: **December 17, 2019**

Nauck M., **Meininger G.**, Sheng D., Terranella L., Stein P. (March 2007) "Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial". Diabetes Obes Metab. Vol. 9 (2): 194-205.

Xu L., Dalla Man C., Charbonnel B., **Meininger G.**, Davies M., Williams-Herman D., Cobelli C., Stein P. (May, 2008) "Effects of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta cell function in patients with type 2 diabetes: A model-based approach". Diabetes Obes Metab Vol. 10 (12): 1212-1220.

Brodovicz K.G., McNaughton K., Uemura N., **Meininger G.**, Girman C.J., Yale S.H. (June 2009) "Reliability and Feasibility of Methods to Quantitatively Assess Peripheral Edema". Clin Med Res. Vol. 7 (1-2): 21-31.

**Meininger G.**, Scott R., Alba M., Shentu Y., Luo E., Amin H., Davies M., Kaufman K., Goldstein B. (December, 2011) "Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes". Diabetes Care. Vol. 34 (12): 2560-2566.

Krobot K., Ferrante S.A., Davies M., Seck T., **Meininger G.**, Williams-Herman D., Kaufman K., Goldstein B. (August 2012) "Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre-specified analysis adjusting for the most recently measured HbA<sub>1c</sub> value". Current Medical Research & Opinion. Vol. 28 (8): Pp. 1281-1287.

Stenlöf K., Cefalu W.T., Kim K-A., Alba M., Usiskin K., Tong C., Canovatchel W., **Meininger G.** (April 2013) "Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise". Diabetes Obes Metab. Vol. 15 (4): Pp. 372-382.

Yale J.F., Bakris G., Cariou B., Yue D., David-Neto E., Xi L., Figueroa K., Wajs E., Usiskin K., **Meininger G.** (May 2013) "Efficacy and Safety of Canagliflozin in Subjects With Type 2 Diabetes And Chronic Kidney Disease". Diabetes Obes Metab. Vol. 15 (5): Pp. 463-473.

Schernthaner G, Gross J, Rosenstock J, Guarisco M, Fu M, Yee J, Kawaguchi M, Canovatchel W, **Meininger G.** (September 2013) "Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control". Diabetes Care. Vol. 36: 2508-2515.

Cefalu T, Leiter L, Yoon K-H, Arias P, Niskanen L, Xie J, Balis D, Canovatchel W, **Meininger G.** (September 2013) "Canagliflozin promotes body weight loss compared with glimepiride while providing glycaemic efficacy in subjects with type 2 diabetes on background metformin: 52-week findings from a randomised, double-blind trial". Lancet. Vol. 382: 941-950.

# CURRICULUM VITAE

EMPLOYEE NAME: **GARY MEININGER, MD**

DATE: **December 17, 2019**

Neal B, Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Stein P, Desai M, Shaw W, Jiang J, Vercruyse F, **Meininger G**, Matthews D. (August 2013) “Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-A randomized placebo-controlled trial”. Am Heart J. Vol. 166 (2): 217-223.

Stenlöf K, Cefalu WT, Kim K-A, Jodar E, Alba M, Edwards R, Tong C, Canovatchel W, **Meininger G**. (October 2013) “Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study”. Current Medical Research & Opinion. Pp. 1-13. doi:10.1185/03007995.2013.850066.

Lavalle-Gonzalez F, Januszewicz A, Davidson J, Tong C, Qiu R, Canovatchel W, **Meininger G**. (December 2013) “Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial”. Diabetologia. Vol. 56 (12): 2582-2592.

Wilding J, Charpentier G, Hollander P, Gonzalez-Galvez G, Mathieu C, Vercruyse F, Usiskin K, Law G, Black S, Canovatchel W, **Meininger G**. (December 2013) “Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial”. Int J Clin Pract. Vol. 67 (12): 1-16.

Balis D, Tong C, **Meininger G**. (December 2013) “Effect of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, on Measurement of Serum 1,5-anhydroglucitol”. J Diabetes. Pp. 1753-0407.

Bailey R, Damaraju CV, Martin S, **Meininger G**, Rupnow M, Blonde L. (January 2014) “Attainment of diabetes-related quality measures with canagliflozin versus sitagliptin”. Am J Manag Care. Vol. 20(Suppl 1): s16-24

Sinclair A, Bode B, Harris S, Vijapurkar U, Mayer C, Fung A, Shaw W, Usiskin K, Desai M, **Meininger G**. (April 2014) “Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies”. BMC Endocr Disord. Vol. 14(1): 37.

Forst T, Guthrie R, Goldenberg R, Yee J, Vijapurkar U, **Meininger G**, Stein P. (May 2014) “Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone”. Diabetes Obes Metab. Vol. 16(5): 467-77.

Qiu R, Capuano G, **Meininger G**. (June 2014) “Efficacy and safety of twice-daily treatment with canagliflozin, a sodium glucose co-transporter 2 inhibitor, added on to metformin monotherapy in patients with type 2 diabetes mellitus”. Journal of Clinical and Translational Endocrinology. Vol. 1(2): 54–60.

Usiskin K, Kline I, Fung A, Mayer C, **Meininger G**. (May 2014) “Safety and tolerability of canagliflozin in patients with type 2 diabetes: pooled analysis of phase 3 study results”. Postgraduate Medicine. Vol. 126(3): 16-34.

# CURRICULUM VITAE

EMPLOYEE NAME: **GARY MEININGER, MD**

DATE: **December 17, 2019**

Yamout H, Perkovic V, Davies M, Woo V, de Zeeuw D, Mayer C, Vijapurkar U, Kline I, Usiskin K, **Meininger G**, Bakris G. (July 2014) “Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy”. Am J Nephrol. Vol. 40(1):64-74.

Yale JF, Bakris G, Cariou B, Nieto J, David-Neto E, Yue D, Wajs E, Figueroa K, Jiang J, Law G, Usiskin K, **Meininger G**. (Oct 2014) “Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease”. Diabetes Obes Metab. Vol. 16(10):1016-27.

Weir MR, Januszewicz A, Gilbert RE, Vijapurkar U, Kline I, Fung A, **Meininger G**. (December 2014) “Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus”. J Clin Hypertens. Vol. 16(12):875-82.

Bailey RA, Vijapurkar U, Meininger G, Rupnow MF, Blonde L. (December 2014) “Diabetes-related quality measure attainment: canagliflozin versus sitagliptin based on a pooled analysis of 2 clinical trials”. Am J Manag Care. Vol. 20(13 Suppl):s296-305.

Ji L, Han P, Liu Y, Yang G, Dieu Van NK, Vijapurkar U, Qiu R, **Meininger G**. (January 2015) “Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea”. Diabetes Obes Metab. Vol. 17(1):23-31.

Leiter LA, Yoon KH, Arias P, Langslet G, Xie J, Balis DA, Millington D, Vercruysse F, Canovatchel W, **Meininger G**. (March 2015) “Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimpiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study”. Diabetes Care. Vol. 38(3):355-64.

Neal B, Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Ways K, Desai M, Shaw W, Capuano G, Alba M, Jiang J, Vercruysse F, **Meininger G**, Matthews D, on behalf of the CANVAS Trial Collaborative Group. (March 2015) “Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes”. Diabetes Care. Vol. 38(3):403-11.

Bode B, Stenlöf K, Harris S, Sullivan D, Fung A, Usiskin K, **Meininger G**. (March 2015) “Long-term Efficacy and Safety of Canagliflozin Over 104 Weeks in Patients Aged 55 to 80 Years With Type 2 Diabetes”. Diabetes Obes Metab. Vol. 17(3):294-303.

Davies MJ, Trujillo A, Vijapurkar U, Damaraju CV, **Meininger G**. (April 2015) “Effect of Canagliflozin on Serum Uric Acid in Patients with Type 2 Diabetes Mellitus”. Diabetes Obes Metab. Vol. 17(4):426-9.

Wilding JP, Blonde L, Leiter LA, Cerdas S, Tong C, Yee J, **Meininger G**. (April 2015) “Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus”. J Diabetes Complications. Vol. 29(3):438-44.

Bailey RA, Vijapurkar U, **Meininger G**, Rupnow MF, Blonde L. (May 2015) “Diabetes-Related Composite Quality End Point Attainment: Canagliflozin Versus Sitagliptin Based on a Pooled Analysis of 2 Clinical Trials”. Clin Ther. Vol. 37(5):1045-54.



# CURRICULUM VITAE

EMPLOYEE NAME: **GARY MEININGER, MD**

DATE: **December 17, 2019**

Cefalu WT, Stenlöf K, Leiter LA, Wilding JP, Blonde L, Polidori D, Xie J, Sullivan D, Usiskin K, Canovatchel W, **Meininger G.** (June 2015) “Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes”. Diabetologia. Vol. 58(6):1183-7.

Gavin JR 3rd, Davies MJ, Davies M, Vijapurkar U, Alba M, **Meininger G.** (September 2015) “The efficacy and safety of canagliflozin across racial groups in patients with type 2 diabetes mellitus”. Curr Med Res Opin. Vol. 31(9):1693-702.

Fulcher G, Matthews DR, Perkovic V, de Zeeuw D, Mahaffey KW, Weiss R, Rosenstock J, Capuano G, Desai M, Shaw W, Vercruysse F, **Meininger G,** Neal B. (September 2015) “Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial”. Diabetes Ther. Vol 6(3):289-302.

Erondu N, Desai M, Ways K, **Meininger G.** (September 2015) “Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program”. Diabetes Care. Vol. 38(9):1680-6.

Blonde L, Woo V, Mathieu C, Yee J, Vijapurkar U, Canovatchel W, **Meininger G.** (November 2015) “Achievement of treatment goals with canagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of randomized controlled trials”. Curr Med Res Opin. Vol. 31(11):1993-2000.

Fulcher G, Matthews DR, Perkovic V, de Zeeuw D, Mahaffey KW, Mathieu C, Woo V, Wysham C, Capuano G, Desai M, Shaw W, Vercruysse F, **Meininger G,** Neal B, on behalf of the CANVAS trial collaborative group. (January 2016) “Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes”. Diabetes Obes Metab. Vol. 18(1):82-91.

Perkovic V, Jardine M, Vijapurkar U, **Meininger G.** (December 2015) “Renal effects of canagliflozin in type 2 diabetes mellitus”. Curr Med Res Opin. Vol. 31(12):2219-31.

Watts NB, Bilezikian JP, Usiskin K, Edwards R, Desai M, Law G, **Meininger G.** (January 2016) “Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus”. J Clin Endocrinol Metab. Vol. 101(1):157-66.

Matthews DR, Zinman B, Tong C, **Meininger G,** Polidori D. (November 2015) “Glycaemic efficacy of canagliflozin is largely independent of baseline  $\beta$ -cell function or insulin sensitivity”. Diabet Med. (doi: 10.1111/dme.13033).

Erondu N, Desai M, Ways K, **Meininger G.** (January 2016) “Response to Comment on Erondu et al. Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program”. Diabetes Care. Vol. 38:1680-1686.

# CURRICULUM VITAE

EMPLOYEE NAME: **GARY MEININGER, MD**

DATE: **December 17, 2019**

Sinclair AJ, Bode B, Harris S, Vijapurkar U, Shaw W, Desai M, **Meininger G.** (March 2016) “Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis”. J Am Geriatr Soc. Vol. 64(3):543-52.

Blonde L, Stenlöf K, Fung A, Xie J, Canovatchel W, **Meininger G.** (May 2016) “Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks”. Postgrad Med. Vol. 128(4):371-80.

Gilbert RE, Weir MR, Fioretto P, Law G, Desai M, Kline I, Shaw W, **Meininger G.** (June 2016) “Impact of Age and Estimated Glomerular Filtration Rate on the Glycemic Efficacy and Safety of Canagliflozin: A Pooled Analysis of Clinical Studies”. Can J Diabetes. Vol. 40(3):247-57.

Davidson JA, Aguilar R, Lavallo González FJ, Trujillo A, Alba M, Vijapurkar U, **Meininger G.** (April 2016) “Efficacy and Safety of Canagliflozin in Type 2 Diabetes Patients of Different Ethnicity”. Ethn Dis. Vol. 26(2):221-8.

Prasanna Kumar KM, Mohan V, Sethi B, Gandhi P, Bantwal G, Xie J, **Meininger G,** Qiu R. (May 2016) “Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from India”. Indian J Endocrinol Metab. Vol. 20(3):372-80.

Patel CA, Bailey RA, Vijapurkar U, **Meininger G,** Blonde L. (August 2016) “A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures”. BMC Health Serv Res. Vol. 16: 356.

Heerspink H, Desai M, Jardine M, Balis D, **Meininger G,** Perkovic P. (January 2017) “Canagliflozin Slows Progression of Renal Function Decline Independent of Glycemic”. J Am Soc Nephrol. Vol. 28(1):368-375.

Qiu R, Balis D, Xie J, Davies MJ, Desai M, **Meininger G.** (March 2017) “Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis”. Curr Med Res Opin. Vol. 33(3):553-562.

Neal B, Perkovic V, Matthews D, Mahaffey K, Fulcher G, **Meininger G,** Erondy N, Desai M, Shaw W, Vercruysse F, Yee J, Deng H, de Zeeuw D. (March 2017) “Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal (CANVAS-R): A randomized, placebo-controlled trial”. Diabetes Obes Metab. Vol. 19(3):387-393.

Merton K, Davies M, Vijapurkar U, Inman D, **Meininger G.** (February 2018) “Achieving the Composite Endpoint of HbA1c, Body Weight, and Systolic Blood Pressure Reduction With Canagliflozin in Patients With Type 2 Diabetes”. Curr Med Res Opin. Vol. 34(2):313-318.

# CURRICULUM VITAE

EMPLOYEE NAME: **GARY MEININGER, MD**

DATE: **December 17, 2019**

Nunez D, Alexander M, Yerges-Armstrong L, Singh G, Byttebier G, Fabbrini E, Waterworth D, **Meininger G**, Galwey N, Wallentin L, White H, Vannieuwenhuysse B, Alazawi W, Kendrick S, Sattar N, and Ferrannini E. (November 2018) “Factors influencing longitudinal changes of circulating liver enzyme concentrations in subjects randomized to placebo in four clinical trials”. Am J Physiol Gastrointest Liver Physiol. Vol. 316(3):G372-G386.

Perkovic V, Jardine M, Neal B, Bompoint S, Heerspink H, Charytan D, Edwards R, Agarwal R, Bakris G, Bull S, Cannon C, Capuano G, Chu P, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler D, Yavin Y, Zhang H, Zinman B, **Meininger G**, Brenner B, and Mahaffey K. (June 2019) “Canagliflozin and Renal Outcomes in Patients with Type 2 Diabetes and Nephropathy”. NEJM. Vol. 380:2295-2306.

Wang L, Voss E, Weaver J, Hester L, Yuan Z, DeFalco F, Schuemie M, Ryan P, Sun D, Freedman A, Alba M, Lind J, **Meininger G**, Berlin J, Rosenthal N. (August 2019) “Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co-transporter 2 inhibitors versus other antihyperglycemic agents”. Pharmacoepidemiol Drug Saf. 1–9.

## Book Chapters and Review Articles

**Meininger G** and Grinspoon S. (May 2002). “Insulin Resistance and Related Metabolic Abnormalities in HIV-Infected Patients”. Endocrinology Rounds. Vol. 1(5):1-5.

**Meininger G** and Grinspoon S. (October 2003). “Chapter V: Abnormalities in Glucose and Insulin in HIV Disease”. Lipodystrophy Syndrome in HIV. Kluwer Academic Publishers. Norwell, Massachusetts.

**Meininger G**, Canovatchel W, Polidori D, Rosenthal N. (2015) “Canagliflozin for the treatment of adults with Type 2 diabetes”. Diabetes Management. Vol. 5(3):183-201.

Rosenthal N, **Meininger G**, Ways K, Polidori D, Desai M, Qiu R, Alba M, Vercruyse F, Balis D, Shaw W, Edwards R, Bull S, Di Prospero N, Sha S, Rothenberg P, Canovatchel W, Demarest K. (November 2015) “Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus”. Ann N Y Acad Sci. Vol. 1358:28-43.

Qiu R, Balis D, Capuano G, Xie J, **Meininger G**. (December 2016) “Canagliflozin: efficacy and safety in combination with metformin alone or with other antihyperglycemic agents in type 2 diabetes”. Diabetes Therapy. Vol. 7(4):659-678.

# CURRICULUM VITAE

## EMPLOYEE NAME: GARY MEININGER, MD

DATE: December 17, 2019

### OTHER PROFESSIONAL ACTIVITIES

Clinical Assistant Professor  
Department of Medicine, Division of Endocrinology  
Rutgers Medical School  
August 2003 – Present

- Attending in Endocrinology at Robert Wood Johnson University Hospital Endocrine Clinic: supervise endocrine fellows, medical residents, and medical students while maintaining a clinic practice (August 2003 – February 2019)
- Lecturer: Robert Wood Johnson Medical School, Second-year medical student lecture, “Pathophysiology of Pituitary and Hypothalamic Disease” (Every February from 2004 to Present)
- Facilitator: Small group endocrinology discussion groups with second-year medical students (Every February 2004 to Present)

Juvenile Diabetes Research Foundation (JDRF)

- Grant reviewer (April 2014)

Foundation for Diabetes Research (FDR), a type 1 diabetes charity

- Member (2011-2019)
- Grant committee (2014 - 2019)
  - Vice President and Grant committee chair (2014 - 2019)
- Executive Board member (2014 - 2019)

Late Development Council, a leadership council of late development leaders across all therapeutic areas within Janssen Research and Development

- Co-founder/co-chair (March 2014 – February 2019)

Harvard Business School Executive Education Research and Development Leadership Program (March 15-20, 2015)

Harvard Medical School, Joslin Diabetes Center Grand Rounds. Invited lecture: “Diabetes Ketoacidosis and Related Events in Type 1 and Type 2 Diabetes Clinical Program: Canagliflozin Experience”. (November 9, 2015)

Industry Representative for the Endocrinologic and Metabolism Advisory Committee (November 2019 – Present)

**CURRICULUM VITAE**  
**EMPLOYEE NAME: GARY MEININGER, MD**  
**DATE: December 17, 2019**

**ACADEMIC AND PROFESSIONAL HONORS**

State University of New York (SUNY) at Binghamton, Binghamton, New York

- Phi Beta Kappa, Junior Year Election
- SUNY Binghamton Foundation Award for Academic Excellence
  - For highest grade point average and overall academic performance
- CRC Press Freshman Chemistry Achievement Award
  - For highest overall performance in freshman chemistry

New York University School of Medicine, New York, New York

- Alpha Omega Alpha (Vice President, 1995 – 1996)
- Maurice Freiman Memorial Award
  - For “overall outstanding and exemplary work”

The Massachusetts General Hospital, Boston, Massachusetts

- Recipient of NIH Individual National Research Service Award July 2001
- One of 5 US Endocrine fellows selected by The Endocrine Society to attend the *GH and Growth Factors - Metabolic Disorders Conference*, Gothenburg, Sweden. May 22-26, 2000

Merck

- Team recipient of Prix Galien USA Award (September 2007)
  - For best pharmaceutical agent (Januvia)

Johnson & Johnson, Inc.

- Recipient of the Johnson Medal (November 2013)
  - Highest honor for research and development at Johnson & Johnson, Inc.; related to leading the canagliflozin (Invokana) type 2 diabetes clinical program
- Recipient of the Janssen SPARK Innovation Award (April 2018)
  - Highest innovation award for research and development at Janssen; related to clinical contribution to the golimumab (Simponi) type 1 diabetes stage 2 and 3 programs